Investing in the Future of Precision Cancer Medicine

Developing a first-in-class, 3rd generation Polo-like Kinase 1 (PLK1) Inhibitor to treat leukemias, lymphomas
and solid tumor cancers

Analyst Coverage


Trovagene, Inc is followed by the analysts. Please note that any opinions, estimates or forecasts regarding Trovagene, Inc's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Trovagene, Inc or its management. Trovagene, Inc does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.